Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma - PubMed (original) (raw)
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma
K Offit et al. N Engl J Med. 1994.
Free article
Abstract
Background: About 40 percent of non-Hodgkin's lymphomas are diffuse lymphomas with a large-cell component (DLLC). Current therapy can induce a long-term remission in half the patients with DLLC, but more intensive treatment has the potential to improve outcome, particularly in patients at high risk for treatment failure. Clinical and cytogenetic markers can identify subgroups at high or low risk. Rearrangement of a novel candidate proto-oncogene, bcl-6, is a possible prognostic indicator in DLLC.
Methods: We performed Southern blot hybridization to detect bcl-6 and bcl-2 gene rearrangement in samples of lymphoma from 102 patients with B-cell DLLC. The results were correlated with the patients' histologic features, age, disease stage, tumor sites and bulk of disease, serum lactate dehydrogenase level, and treatment outcome.
Results: Rearranged bcl-6 was found in 23 cases, and rearranged bcl-2 in 21 cases. Nineteen of the patients with rearranged bcl-6 had extranodal DLLC, two had primary splenic lymphomas, and only one had bone marrow involvement. Thirty-six months after diagnosis, the proportion with freedom from progression of disease was projected to be 82 percent (95 percent confidence interval, 66 to 98 percent) among the patients with rearranged bcl-6, as compared with 56 percent (95 percent confidence interval, 43 to 70 percent) for the patients with germ-line bcl-6 and bcl-2 and 31 percent (95 percent confidence interval, 8 to 53 percent) for the patients with rearranged bcl-2. The status of the bcl-6 gene was an independent prognostic marker of survival and freedom from disease progression in a multivariate model and added predictive value to established prognostic signs.
Conclusions: Rearrangement of the bcl-6 gene correlated with a favorable clinical outcome in DLLC and may thus serve as a prognostic marker in patients with this form of malignant lymphoma.
Comment in
- bcl-6 in lymphoma--sorting out a wastebasket?
Kluin PM. Kluin PM. N Engl J Med. 1994 Jul 14;331(2):116-8. doi: 10.1056/NEJM199407143310210. N Engl J Med. 1994. PMID: 8208254 No abstract available.
Similar articles
- Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas.
Pescarmona E, De Sanctis V, Pistilli A, Pacchiarotti A, Martelli M, Guglielmi C, Mandelli F, Baroni CD, Le Coco F. Pescarmona E, et al. J Pathol. 1997 Nov;183(3):281-6. doi: 10.1002/(SICI)1096-9896(199711)183:3<281::AID-PATH1134>3.0.CO;2-Z. J Pathol. 1997. PMID: 9422982 - Analysis of the BCL-6 gene configuration in diffuse B-cell non-Hodgkin's lymphomas and Hodgkin's disease.
Pescarmona E, Lo Coco F, Pacchiarotti A, Rapanotti MC, Cimino G, Di Paolo B, Baroni CD. Pescarmona E, et al. J Pathol. 1995 Sep;177(1):21-5. doi: 10.1002/path.1711770105. J Pathol. 1995. PMID: 7472775 - An immunophenotypic and molecular study of primary large B-cell lymphoma of bone.
Huebner-Chan D, Fernandes B, Yang G, Lim MS. Huebner-Chan D, et al. Mod Pathol. 2001 Oct;14(10):1000-7. doi: 10.1038/modpathol.3880425. Mod Pathol. 2001. PMID: 11598170 - Identification of genetic lesions associated with diffuse large-cell lymphoma.
Dalla-Favera R, Ye BH, Lo Coco F, Gaidano G, Lista F, Knowles DM, Louie DC, Offit K, Chaganti RS. Dalla-Favera R, et al. Ann Oncol. 1994;5 Suppl 1:55-60. doi: 10.1093/annonc/5.suppl_1.s55. Ann Oncol. 1994. PMID: 8172819 Review. - Bcl-6 protein expression in normal and neoplastic lymphoid tissues.
Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L. Falini B, et al. Ann Oncol. 1997;8 Suppl 2:101-4. Ann Oncol. 1997. PMID: 9209651 Review.
Cited by
- Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.
Katzenberger T, Ott G, Klein T, Kalla J, Müller-Hermelink HK, Ott MM. Katzenberger T, et al. Am J Pathol. 2004 Aug;165(2):481-90. doi: 10.1016/S0002-9440(10)63313-5. Am J Pathol. 2004. PMID: 15277222 Free PMC article. - DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA, Kleo K, Lenze D, Oker E, Dimitrova L, Hummel M. Akpa CA, et al. PLoS One. 2019 Aug 16;14(8):e0220681. doi: 10.1371/journal.pone.0220681. eCollection 2019. PLoS One. 2019. PMID: 31419226 Free PMC article. - Clinicopathological analysis of diffuse large B-cell lymphoma using molecular biomarkers: a retrospective analysis from 7 Hungarian centers.
Balikó A, Szakács Z, Kajtár B, Ritter Z, Gyenesei A, Farkas N, Kereskai L, Vályi-Nagy I, Alizadeh H, Pajor L. Balikó A, et al. Front Oncol. 2023 Sep 8;13:1224733. doi: 10.3389/fonc.2023.1224733. eCollection 2023. Front Oncol. 2023. PMID: 37746254 Free PMC article. - Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.
Villanueva A, Toffanin S, Llovet JM. Villanueva A, et al. Curr Opin Oncol. 2008 Jul;20(4):444-53. doi: 10.1097/CCO.0b013e328302c9e9. Curr Opin Oncol. 2008. PMID: 18525342 Free PMC article. Review. - Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma.
Migliazza A, Martinotti S, Chen W, Fusco C, Ye BH, Knowles DM, Offit K, Chaganti RS, Dalla-Favera R. Migliazza A, et al. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12520-4. doi: 10.1073/pnas.92.26.12520. Proc Natl Acad Sci U S A. 1995. PMID: 8618933 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources